ecrin-mdr-crcClinical2012Metastatic Colorectal CancerColorectal NeoplasmsMetastatic Colorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2140857Italy12VECTIBIX*INFUS 1FL 5ML 20MG/MLPanitumumabCetuximab-refractoryVECTIBIX*INFUS 1FL 10ML 20MG/MECRIN MDRActive, not recruitingfalseA Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal CancerThe purpose of this study is to assess if panitumumab is active enough to warrant comparative studies in patients with metastatic colorectal cancer that has progressed after treatment with cetuximab.2012-12-152140857NCT018019042010-024490-39